Therefore, we infer that a high activation status of the TGFB pathway may enhance the sensitivity of SCLC patients to platinum-based chemotherapy by activating immunity, inhibiting repair, and promoting apoptosis (Figure 2). This evidence concerns the gene TGFB1 and small cell lung carcinoma.